Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas.

Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O.

Histopathology. 2012 Jun;60(7):1073-83. doi: 10.1111/j.1365-2559.2011.04163.x. Epub 2012 Feb 20.

PMID:
22348389
2.

Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Jan;25(1):122-30. doi: 10.1038/modpathol.2011.143. Epub 2011 Oct 7.

3.

Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.

Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O.

Mod Pathol. 2009 Apr;22(4):499-507. doi: 10.1038/modpathol.2008.234. Epub 2009 Jan 16.

4.

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2011 Aug;24(8):1146-55. doi: 10.1038/modpathol.2011.70. Epub 2011 Apr 8.

5.

Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Virchows Arch. 2009 Nov;455(5):413-22. doi: 10.1007/s00428-009-0844-5. Epub 2009 Oct 24.

PMID:
19855998
6.

Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.

Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O.

Mod Pathol. 2008 Feb;21(2):115-24. Epub 2007 Dec 14.

7.

Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma.

Kato M, Yamamoto S, Takano M, Matsubara O, Furuya K.

Int J Gynecol Pathol. 2012 May;31(3):254-63. doi: 10.1097/PGP.0b013e318237d66c.

PMID:
22498943
8.

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.

9.

PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.

Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O.

J Pathol. 2011 Oct;225(2):189-94. doi: 10.1002/path.2940. Epub 2011 Jul 7.

PMID:
21735444
10.

Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Histopathology. 2010 May;56(6):740-9. doi: 10.1111/j.1365-2559.2010.03551.x.

PMID:
20546339
11.

Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas.

Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, Umaki T, Onozato K, Shitashige M, Yamaguchi U, Ono M, Tsuchida A, Aoki T, Inazawa J, Hirohashi S, Yamada T.

Clin Cancer Res. 2008 Sep 1;14(17):5348-56. doi: 10.1158/1078-0432.CCR-08-0075.

12.

Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.

Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O.

J Pathol. 2008 Sep;216(1):103-10. doi: 10.1002/path.2386.

PMID:
18600856
13.

Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type.

Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T, Matsubara O.

Mod Pathol. 2007 Dec;20(12):1278-85. Epub 2007 Sep 14.

14.

Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.

Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K, Tamai S, Matsubara O.

Am J Surg Pathol. 2007 Jul;31(7):999-1006.

PMID:
17592265
15.

[Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].

Xie D, Yang GF, Chen YQ, Jiang LF, Xiao LZ.

Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):911-4. Chinese.

PMID:
17533742
16.

HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.

Mayr D, Kanitz V, Amann G, Engel J, Burges A, Löhrs U, Diebold J.

Histopathology. 2006 Jan;48(2):149-56.

PMID:
16405663
17.

HER-2/neu amplification and overexpression in endometrial carcinoma.

Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH.

Int J Gynecol Pathol. 1999 Apr;18(2):138-43.

PMID:
10202671
18.
19.

Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.

Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.

Cancer. 2012 Jun 1;118(11):2846-57. doi: 10.1002/cncr.26598. Epub 2011 Dec 2.

20.

Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Matsuo Y, Tashiro H, Yanai H, Moriya T, Katabuchi H.

Med Mol Morphol. 2015 Sep;48(3):146-54. doi: 10.1007/s00795-014-0090-z. Epub 2014 Nov 15.

PMID:
25398420

Supplemental Content

Support Center